ImmuCell Announces Strong Preliminary Sales Results for Q4 and Full Year 2024

ImmuCell Corporation (NASDAQ: ICCC) recently disclosed its preliminary, unaudited sales figures for the fourth quarter and full year that ended on December 31, 2024. The company, headquartered in Portland, Maine, focuses on developing, manufacturing, and marketing practical products that enhance the health and productivity of dairy and beef cattle. For the three-month period concluding on […]

Leave a Reply

Your email address will not be published.

Previous post Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update
Next post NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_